GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (NAS:GLYC) » Definitions » E10

GLYC (GlycoMimetics) E10 : $-121.77 (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

GlycoMimetics's adjusted earnings per share data for the three months ended in Mar. 2025 was $-4.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-121.77 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-07-09), GlycoMimetics's current stock price is $15.70. GlycoMimetics's E10 for the quarter that ended in Mar. 2025 was $-121.77. GlycoMimetics's Shiller PE Ratio of today is .


GlycoMimetics E10 Historical Data

The historical data trend for GlycoMimetics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoMimetics E10 Chart

GlycoMimetics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -147.22 -123.94 -124.72

GlycoMimetics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -123.94 -131.41 -128.74 -124.72 -121.77

Competitive Comparison of GlycoMimetics's E10

For the Biotechnology subindustry, GlycoMimetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoMimetics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's Shiller PE Ratio falls into.


;
;

GlycoMimetics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GlycoMimetics's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-4/134.9266*134.9266
=-4.000

Current CPI (Mar. 2025) = 134.9266.

GlycoMimetics Quarterly Data

per share eps CPI Adj_EPS
201506 51.000 100.684 68.345
201509 -38.000 100.392 -51.072
201512 -47.000 99.792 -63.547
201603 -40.000 100.470 -53.718
201606 -41.000 101.688 -54.402
201609 -34.000 101.861 -45.037
201612 -36.000 101.863 -47.685
201703 -34.000 102.862 -44.599
201706 -30.000 103.349 -39.166
201709 -24.000 104.136 -31.096
201712 -27.000 104.011 -35.025
201803 -33.000 105.290 -42.289
201806 -26.000 106.317 -32.997
201809 -27.000 106.507 -34.205
201812 -32.000 105.998 -40.733
201903 -33.000 107.251 -41.516
201906 -37.000 108.070 -46.195
201909 -31.000 108.329 -38.611
201912 -34.000 108.420 -42.312
202003 -18.000 108.902 -22.302
202006 -32.000 108.767 -39.696
202009 -29.000 109.815 -35.632
202012 -32.000 109.897 -39.288
202103 -28.000 111.754 -33.806
202106 -28.000 114.631 -32.957
202109 -34.000 115.734 -39.638
202112 -33.000 117.630 -37.853
202203 -28.000 121.301 -31.145
202206 -25.000 125.017 -26.982
202209 -16.000 125.227 -17.239
202212 -19.000 125.222 -20.473
202303 -17.000 127.348 -18.012
202306 -13.000 128.729 -13.626
202309 -14.000 129.860 -14.546
202312 -14.000 129.419 -14.596
202403 -17.000 131.776 -17.406
202406 -16.000 132.554 -16.286
202409 -15.000 133.029 -15.214
202412 -11.000 133.157 -11.146
202503 -4.000 134.927 -4.000

Add all the adjusted EPS together and divide 10 will get our e10.


GlycoMimetics  (NAS:GLYC) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


GlycoMimetics E10 Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoMimetics Business Description

Traded in Other Exchanges
Address
P.O. Box 65, Monrovia, MD, USA, 21770
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Executives
Invus Public Equities, L.p. 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Edwin Rock officer: Chief Medical Officer 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Brian M. Hahn officer: CFO C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Daniel M Junius director C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Bruce S Johnson officer: SVP & Chief Commercial Officer 9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850
Chinmaya Rath officer: SVP and Chief Business Officer 9708 MEDICAL CENTER DR., ROCKVILLE MD 20850
Invus Public Equities Advisors, Llc 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Artal Group S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
S.a. Westend 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Administratiekantoor Westend Stichting 10 percent owner CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD
Artal International Management S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Amaury Wittouck 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661
Scott D Sandell 10 percent owner
Harout Semerjian director, officer: Chief Executive Officer 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950